🔗 Share this article Social Media Influencers Driving Parallel Trade for Unlicensed Slimming Drug An underground market for unlicensed weight-loss medications is propelled by TikTok fitness influencers and sellers on communication apps, according to new investigations. Experimental Drug Acquiring Traction Online Retatrutide, which remains in research studies, is being advertised by online personalities for its supposed weight-reducing properties. Viewers are urged to contact these profiles directly for supplier links, while also receiving promotional offers. Active Commerce on Social Networks Separately, a flourishing trade exists on messaging services, where communities with numerous of participants share comparison images, administration instructions and assertions of rapid UK delivery. Sellers promote the drug there before directing buyers to other platforms for transactions. Learning About The Experimental Drug This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being promoted online as the next Ozempic. Medical Experts Express Worries Nevertheless, physicians and pharmacists have warned that the sale of what is still an unapproved drug in the UK is worrisome and could lead to individuals administering products of unknown origin. Some experts said the demand for the experimental drug could be linked to the increasing price of licensed weight loss products such as Mounjaro. Legal Position and Implementation Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012. Some content creators try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still violate medicines, advertising, and consumer laws, potentially leading to penalties, prosecution or imprisonment. Platform Response and Material Elimination According to the social media company, the service has taken down problematic content and prohibited associated keywords and query recommendations. The organization said it was dedicated to maintaining the service secure and investing in strengthening compliance measures. Online Trading Activities Investigations also found groups with up to nine thousand participants selling the experimental drug using Telegram's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays channels with thousands of members, populated with images of slimming results, glowing reviews and detailed instructions for preparing or injecting at residence. Within moments of entering one community, a seller shared contact information, where most transactions occur. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about weight, health issues or past usage. Product Details and Costs Inside these communities, posts show black plastic packages with postal service stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.” Buyers can select between dry substance containers, mixed at residence with purified liquid, or ready-to-use pens usually sold at £160 for 20 milligrams. When asked how much time a pen should last, vendors give conflicting answers varying between a several days to “depends on your body”. Platform Moderation and Safety Actions A representative for the messaging service said it regularly moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”. Healthcare Professional Cautions “People are administering substances they cannot confirm. Even if the research behind this drug is sound, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmacy at Chemist4U. A medical professional of Asda Online Doctor linked the increase in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the environment they were made in was clean,” she explained. Her team has already encountered patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is gambling with your health,” said the doctor. “These materials could be contaminated or incorrectly dosed.” Producer Position A spokesperson from Eli Lilly said retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority globally. “Therefore at this time no one can market [it] for human use,” they explained, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may subject users to potentially significant medical dangers”.